Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will hold its 3Q20 earnings conference call with the financial community on 15th October 2020 at 8:00 AM Eastern Time.
The conference call will be webcast live on Internet at www.brainstorm-cell.com
Earnings Expectation
Brainstorm Cell Therapeutics Inc. is expected to report third quarter earnings results, before market open, on Thursday 15th October 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.26 per share. Looking ahead, the full year loss are expected at $ 1.15 per share.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patients own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinsons disease, Huntingtons disease, and autism spectrum disorder.
